Sagimet Biosciences Inc. Cash Flow Statement
SGMT|2 years of annual SEC 10-K data (FY2023-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$24M
FY2024
Free Cash Flow
N/A
FY2024
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2024
Sagimet Biosciences Inc. used $24M in operating cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 |
|---|---|---|
| Net Income | -$27.9M | -$30.5M |
| Operating Cash Flow | -$23.8M | -$24.5M |